Liraglutide
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Novo Nordisk · Phase 3 · Completed · Enrollment 3731
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68) | Obesity or overweight | 3.0mg | 68 | n/r | 0.69% at week 56 |
| Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68) | Obesity or overweight | 3.0mg | 68 | n/r | 2.91% at week 56 |
| Liraglutide Placebo, no Pre-diabetes | Obesity or overweight | n/r | 68 | n/r | 0.28% at week 56 |
| Liraglutide 3.0mg, Pre-diabetes | Obesity or overweight | 3.0mg | 68 | n/r | n/r |
| Liraglutide Placebo, Pre-diabetes | Obesity or overweight | n/r | 68 | Efficacy | n/r |
| Liraglutide 3.0 mg (56-Week) | Obesity or overweight | 3.0 mg | 56 | Efficacy | n/r |